SCHEMBL3473738

SCHEMBL3473738

CC(=O)Nc1ccc(NC(=O)c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.57
MAPT P10636 9/20 0.57
POLB P06746 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.55
TP53 P04637 2/20 0.55
RXRA P19793 3/20 0.55
NR1H2 P55055 3/20 0.55
NR1H3 Q13133 3/20 0.55
THRB P10828 3/20 0.52
ORAI1 Q96D31 1/20 0.51
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3474844 0.94 RXRA (0.55) PTGS2MAPTPOLBSMN1; SMN2TP53
SCHEMBL3471118 0.94 MAPT (0.57) PTGS2MAPTPOLBSMN1; SMN2TP53
SCHEMBL3471938 0.92 ORAI1 (0.60) PTGS2MAPTPOLBSMN1; SMN2TP53
SCHEMBL3471277 0.92 MAPT (0.57) PTGS2MAPTPOLBSMN1; SMN2TP53
SCHEMBL3471324 0.92 MAPT (0.59) PTGS2MAPTPOLBSMN1; SMN2TP53
SCHEMBL3474820 0.92 RXRA (0.51) PTGS2MAPTPOLBSMN1; SMN2TP53
SCHEMBL3474142 0.91 MAPT (0.59) PTGS2MAPTPOLBSMN1; SMN2TP53
SCHEMBL3472102 0.91 MAPT (0.61) PTGS2MAPTPOLBSMN1; SMN2TP53
SCHEMBL3472857 0.90 MAPT (0.57) PTGS2MAPTPOLBSMN1; SMN2TP53
SCHEMBL3473293 0.90 RXRA (0.54) PTGS2MAPTPOLBSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 PTGS2 1500/4885MAPT 4737/4885POLB 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.